source
- FDA rejects Capricor's Duchenne cell therapy again, citing major trial flawsCapricor Therapeutics' deramiocel cell therapy for Duchenne muscular dystrophy was denied by the FDA for a second time. The agency highlighted significant issues with the trial design and data, le…
- FDA delays decision on Belite Bio's Stargardt disease drug to May 12The FDA announced it will extend its review of Belite Bio's new drug application for tinlarebant, an oral small-molecule intended to treat Stargardt disease type 1, moving the PDUFA action date fro…